HEALTHSTORY 672· JUNE 20, 2026

Daraxonrasib Doubles Average Survival in Pancreatic Cancer, UCLA-Led Trial Shows

A UCLA-co-led international study presented May 31 at the American Society of Clinical Oncology annual meeting in Chicago reported that pancreatic cancer patients treated with daraxonrasib survived an average of 13.2 months — nearly double…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 671Nuclear Bros: Silicon Valley's Young Founders Race to Restart American Atomic Power NEXT STORY 673 →U.S. Confirms Second Strike on Iran Targeting Air Defenses as Oil Prices Surge

Keep reading

More from the desk.

21HEALTH

Seven months after launch, Aurora Therapeutics scraps its lead gene-editing program and cuts staff

Personalized CRISPR therapies, gene-editing treatments built around one patient's specific mutation rather than a disease shared by millions, just lost one of their early backers. Aurora Therapeutics has scrapped its lead program and laid…

health2 MIN

36HEALTH

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market. That concept, called a "duty to innovate," was at the center of a case brought…

health2 MIN

47HEALTH

Trump administration shifts 340B drug program from upfront discounts to rebates, drawing hospital backlash

A federal law requires pharmaceutical manufacturers to sell discounted medicines to specific hospitals and clinics. That discount mechanism, the foundation of the 340B Drug Pricing Program, is now being reshaped. The Trump administration…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk